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PURPOSE. Cone-rod dystrophy (CRD) is a rare hereditary eye disorder that causes progres-
sive degeneration of cone and rod photoreceptors. More than 30 genes, including RAB28,
have been associated with CRD; however, only a few RAB28 variants have been reported
to be associated with CRD. In this study, we describe two brothers with CRD and a
homozygous missense variant, c.55G>A (p.Gly19Arg), in RAB28.
METHODS. The missense variant was identified as part of a study investigating underly-
ing genetic defects in a large patient cohort (n = 667) using targeted next-generation
sequencing of 125 genes associated with retinal dystrophy. Cellular localization of
RAB28 and ciliogenesis in patient fibroblasts were investigated by immunofluorescence
microscopy. The effect of the missense variant on RAB28 expression level was investi-
gated by quantitative real-time PCR.
RESULTS. Two brothers of a consanguineous couple presented with CRD, postaxial poly-
dactyly (PAP), and myopia. Both brothers had a homozygous missense RAB28 variant
located in the G1 box of the guanosine triphosphate/guanosine diphosphate binding
domain of RAB28. This missense variant caused a considerable reduction of RAB28 local-
ized to the cilia, whereas ciliogenesis seemed unaffected.
CONCLUSIONS. The missense variant in RAB28 is classified as likely pathogenic with func-
tional effect on protein localization. The combination of retinal dystrophy and PAP are
well known from ciliopathies; however, more data are needed to finally conclude that
the RAB28 variant described here is the cause of PAP in these brothers.
Keywords: cone-rod dystrophy, RAB28, primary clilium, localization, molecular genetics
I nherited retinal diseases (IRDs) are a major cause ofvisual impairment and affect approximately 1 in 3500.1
It is a clinically and genetically heterogeneous group of
disorders with around 200 associated genes. A common
feature is the malfunction of the photoreceptors in the
retina. In some cases the cones are predominantly affected;
in others, the rods. Both stationary and progressive forms
exist, and clinical symptoms and age of onset may vary
from severe congenital visual impairment to onset of
symptoms in adulthood. IRDs can be isolated or part
of a systemic disorder. All modes of Mendelian inher-
itance as well as mitochondrial inheritance have been
observed. Rare cases of digenic inheritance have also been
reported.2
Genes associated with IRDs are expressed either in the
photoreceptors (rods or cones, or both) or in the supporting
retinal pigment epithelium (RPE) cells. The most frequent
form of IRD is retinitis pigmentosa (RP), presenting with
night blindness and peripheral concentric visual field loss,
caused by progressive degeneration of the rod photorecep-
tors and subsequent degeneration of the cones leading to
blindness. Cone-rod dystrophy (CRD) is characterized by an
initial loss of cones and symptoms of central vision loss,
photophobia, progressive visual field loss, and color vision
deficiency. In later stages, the rods also degenerate, typically
leading to night blindness. Clinical distinction between RP
and CRD can be difficult, especially in the late stages. Several
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FIGURE 1. (A) Localization of sequence variants in RAB28 thought to cause CRD. (B) Gly19 is a conserved amino acid through evolution,
as are surrounding amino acids.
treatment strategies for IRDs are under development; among
these, gene therapy has given promising results.
RAB28 (MIM 612994) belongs to the RAB subfamily of
the RAS oncogene family of Ras-related small GTPases.
RAB GTPases function as molecular switches to control
vesicle transport, vesicle budding, and membrane fission,
and they regulate vesicle trafficking between organelles.
In Caenorhabditis elegans (C. elegans), rab-28 has been
linked to an intraflagellar transport (IFT) cargo through
the Bardet–Biedl syndrome (BBS) cargo-adaptor protein
complex (BBSome).3
RAB28 localizes to 4p15.33 and has two pseudogenes,
located on chromosome 9 and X chromosome, respectively.
The gene consists of nine exons, and alternative splicing
gives rise to three isoforms differing in C-terminus.4 Two
of the isoforms contain a C-terminal CAAX farnesylation
motif.4,5 RAB28 tissue expression patterns differ among
the isoforms, but they are all expressed in the retina.6 In
C. elegans, rab-28 is expressed only in ciliated sensory
neurons.3 In 2013, sequence changes in RAB28 were iden-
tified for the first time as the genetic cause of CORD18.6 To
date, only five RAB28 variants are reported in the Human
Gene Mutation Database (Fig. 1A).7
We report a family with two affected brothers of a consan-
guineous couple with a homozygous sequence variant,
c.55G>A (p.Gly19Arg), located in the conserved guanosine
triphosphate (GTP)/guanosine diphosphate (GDP) binding
domain of RAB28 (Fig. 1B). Previously reported RAB28 vari-
ants have been associated with isolated CRD. Whether the
postaxial polydactyly (PAP) observed in the affected broth-
ers is also caused by the RAB28 variant requires more inves-
tigation. We provide a thorough ophthalmological descrip-
tion of the affected brothers as well as retrospective data
from their medical history.
METHODS
The project was performed according to the Declaration of
Helsinki and approved by the Regional Ethics Committee.
Written informed consent was obtained before the molecular
genetic testing.
Clinical Examinations
Retrospective data from the 1970s from the National Eye
Clinic for the Visually Impaired in Copenhagen, Denmark
(NEC) archive were reviewed. Both brothers (IV-1 and IV-3)
were re-examined in 2018 by spectral domain optical coher-
ence tomography (OCT) and by ultra-wide-field pseudocolor
and autofluorescence fundus imaging (Optos, Dunfermline,
UK). International Society for Clinical Electrophysiology of
Vision standard electroretinography (ERG) and Goldmann
(III4e) kinetic visual fields were performed on the younger
sibling (IV-3) with better preserved visual function. The
brothers, IV-1 and IV-3, informed us of other clinical issues
in this family.
Molecular Genetic Analysis
Genomic DNA was extracted from peripheral blood using
standard protocols. Targeted next-generation sequencing
was performed as described previously.8 Briefly, 125 genes,
including RAB28, were sequenced using the custom Nimble-
Gen SeqCap Target Enrichment KIT (NimbleGen, Madi-
son, WI, USA) with capture and enrichment of all coding
exons, 5′ and 3′ untranslated regions, and 20-bp flank-
ing intronic regions. The enriched DNA libraries were
sequenced using the Illumina HiSeq 2000 platform (Illu-
mina, Inc., San Diego, CA, USA). Interpretation and classifi-
cation of variants was performed according to the American
College of Medical Genetics and Genomics (ACMG) guide-
lines.9 In silico analysis of missense variants was performed
using Align GVGD,10,11 SIFT,12 MutationTaster,13 PolyPhen-
2,14 and CADD software.15
Cell Studies
Fibroblasts from the patients and one control were
obtained by skin biopsy. The cells were cultured in
Dulbecco’s modified Eagle’s medium (DMEM)/F-12 + Gibco
GlutaMAX(#31331-028; Thermo Fisher Scientific, Waltham,
MA, USA) supplemented with Gibco 10% fetal bovine serum
(FBS) (#10270-106) and Gibco 1% penicillin/streptomycin
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(p/s) (#15140-122). Two different cultures from each patient
were established. Cilia were induced by culturing the cells
in reduced-serum medium containing 0.5% FBS and 1% p/s
for 48 hours unless otherwise specified.
Treatment with siRNA against RAB28 (#SI03024686 and
#SI00061705; Qiagen, Hilden, Germany) and with AllStars
Negative Control scramble siRNA (#SI03650318; Qiagen)
was performed using the DharmaFECTsystem (#T-2001-03;
Dharmacon, Lafayette, CO, USA). Twenty-four hours after
siRNA transfection, the cells were cultured in reduced-serum
medium for 48 hours followed by fixation for immunofluo-
rescence microscopy, or they were used for RNA extraction.
For immunofluorescence microscopy, the cells were grown
on glass slides.
Total RNA was extracted using the GeneJET RNA
Purification Kit (#K0732; Thermo Fisher Scientific), and
cDNA was synthesized using the High Capacity cDNA
Reverse Transcription Kit (#4368814; Applied Biosys-
tems, Foster City, CA, USA). Real-time quantitative PCR
(qRT-PCR) was performed using TaqMan probes against
RAB28 (#Hs01017480_m1; Applied Biosystems) and GAPDH
(#Hs99999905_m1; Applied Biosystems). The 7500 Fast
Real-Time PCR System (Applied Biosystems) was used for
qRT-PCR amplification, and the relative standard curve
method was used for calculation. RAB28 mRNA expression
levels were normalized to GAPDH mRNA.
For immunofluorescence microscopy, the cells were fixed
using 4% paraformaldehyde (1000.1000; Hounisen, Skander-
borg, Denmark) for 15 minutes at room temperature, perme-
abilized using 0.2% TritonX-100 (Sigma Aldrich, St. Louis,
MO, USA) in PBS for 15 minutes and blocked for 30 minutes
in 3% bovine serum albumin. The fixed cells were incu-
bated with the primary antibodies against RAB28 (#PA5-
68303; Thermo Fisher Scientific) diluted 1:1000 and Arl13B
(#ab136648; Abcam, Cambridge, UK) or anti-acetylated alfa-
tubulin antibody (Ac-TUB) (T6793; Sigma-Aldrich) diluted
1:1000, for either 2 hours at room temperature or 16 hours
at 4°C. Incubation with secondary antibodies Alexa Flour
Goat Anti-Rabbit 488 (#A11008; Life Technologies, Carlsbad,
CA, USA) and Alexa Flour Donkey Anti-Mouse 546 (#A10036,
Life Technologies) was carried out in the dark for 45 minutes
at room temperature. DAPI (#D9542; Sigma-Aldrich) was
used to stain the nucleus. For each cell line, at least 100
primary cilia were analyzed per treatment.
Statistical analysis was performed using t-tests or χ2 tests
as indicated. Levels of significance were classified as *P <
0.05, **P < 0.005, and ***P < 0.0005.
RESULTS
Clinical features are listed in Table 1, and the family pedi-
gree is shown in Figure 2. Brothers IV-1 and IV-3 had their
first visit at NEC in 1971. They both initially presented with
high myopia in early childhood. In their teens, both were
diagnosed with progressive CRD, and the diagnosis was later
confirmed with ERGs revealing undetectable cone responses
and moderate to severe reduced rod responses. In adult-
hood, both developed glaucoma and cataract. At the most
recent clinical examination in 2018, IV-1 presented with only
light perception, but IV-3 still had useful navigation vision
and was able to hold a part-time office job. Both presented
with photophobia, absent color vision, and constricted visual
fields but only minimal night blindness. The ocular fundus
phenotypes in 2018 are shown in Figure 3. Furthermore,
both IV-1 and IV-3 had PAP with an extra finger. Only IV-
FIGURE 2. Pedigree of the family. For simplicity not all family
members mentioned in the text are shown in the figure. Open
circles and squares are unaffected females and males, respectively.
Filled squares indicate a symptom depending on location in the
square.
1 and IV-3 had the symptoms of CRD and PAP. Due to
the combination of retinal dystrophy and PAP, they were
suspected of BBS, and molecular genetic analysis of the BBS
genes (BBS1–BBS17) was performed for IV-3; however, the
BBS diagnosis could not be confirmed.
Several other clinical findings were described in the
family. Deuteranomaly (green) was found in IV-2 and in the
brother of III-1 (not shown on the pedigree). Furthermore,
a dominant form of myopia was observed in III-2, IV-1, IV-2,
and IV-3 and in the daughter of IV-2 (not shown on the pedi-
gree). For IV-1 and IV-3, it could not be determined whether
their myopia was related to the retinal dystrophy or if they
inherited the apparently dominant myopia segregating in
the family, or both. Some of the family members also had
prostate cancer (III-2, IV-1, IV-2, and IV-3).
Genetic Studies
Both brothers were homozygous for c.55G>A (p.Gly19Arg).
Gly19 is a conserved amino acid located in the G1 box of
the G domain of RAB28 (Fig. 1B). Five in silico prediction
programs predict p.Gly19Arg to be pathogenic. The vari-
ant is reported in 2 out of 257.380 alleles in the gnomAD
database.16 p.Gly19Arg segregates with disease in this family
in an autosomal recessive inheritance pattern; however, the
family is small, and brother IV-2 was not available for analy-
sis because he died from prostate cancer. This study shows
that p.Gly19Arg alters the function of RAB28. Consequently,
following the ACMG guidelines for interpretation of vari-
ants,9 c.55G>A is classified as likely pathogenic.
Cell Studies
Previous studies have found rab-28 to be localized in neuro-
cilia in C. elegans3 and in the RPE cells and outer segments
of photoreceptors in mice.17 Jensen et al.3 also linked rab-
28 as an IFT cargo through the BBSome. To validate the
pathogenicity of the human p.Gly19Arg RAB28 variant, the
expression level of RAB28 mRNA and the cellular localiza-
tion of the RAB28 protein were investigated in fibroblast
cells obtained from the two affected brothers and control
cells for comparison.
Briefly, cells from IV-1, IV-3, and a control individual were
grown under standard growth conditions, or under reduced-
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FIGURE 3. Ultra-wide-field fundus image (A) and blue-light autofluorescence (C) image of IV-3 shows peripapillary atrophy and well-
circumscribed chorioretinal atrophy in the macula; furthermore, two to three rows of multiple nummular atrophic and heavily pigmented
chorioretinal areas are noted. Severely attenuated retinal vessels, especially arteries, are observed. (B) OCT shows an ellipsoid zone and
outer limiting membrane preserved temporal to fovea (white arrow) and intraretinal cysts and lamellar retinal hole formation in the fovea
(asterisk). (D) Ultra-wide-field fundus image of IV-1 demonstrates extensive atrophy of the retina and the choroid around the disk and
nasal midperiphery and well-demarcated retina and choroid atrophy in the macula. As for IV-3, severely attenuated retinal vessels, especially
arteries, are observed. The far-peripheral retina is relatively spared in IV-1. (E, F) Progression of retinal degeneration over time. Right-eye
color fundus photographs of younger sibling in 1993 (E) and in 2018 (F). Central chorioretinal atrophy with hyperpigmentation has developed
in the macula. Peripapillary and nasal midperipheral atrophy has significantly progressed. Images were taken with different cameras and
different angle lenses; therefore, direct comparison of vascular changes was complicated. However, vessels seem to have straightened slightly
over time.
serum conditions to induce formation of the primary cilium
(referred to as cilium hereafter).
Investigation of the RAB28 expression level by qRT-
PCR revealed that RAB28 mRNA was expressed in both
control and patient cells, indicating that the variant did
not affect the expression level; furthermore, the expres-
sion level was significantly increased under reduced-serum
conditions (Fig. 4A). Investigation of the cellular localiza-
tion of the RAB28 protein in control cells by immunofluo-
rescence microscopy showed that 73% of the cilia stained
positive for RAB28 (Table 2), consistent with ciliary local-
ization of RAB28 in human cells (Fig. 4B). Interesting, the
patient cell lines showed a significant reduction in the
number of RAB28-positive cilia (36% RAB28-positive cilia
each) (Table 2).
To verify the specificity of the RAB28 antibody we
performed siRNA-mediated knock down of RAB28 in the
control fibroblasts. Treatment with siRNA against RAB28
reduced the number of RAB28-positive cilia significantly
(from 73% to 28% RAB28-positive cilia), whereas treatment
with a negative control siRNA (siScramble) did not, confirm-
ing the specificity of the RAB28 antibody (Table 2).
We subsequently investigated whether ciliogenesis was
affected by the RAB28 variant by assessing the percentage
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FIGURE 4. (A) Serum reduction leads to increased expression of RAB28. Expression profiles of RAB28 mRNA were normalized to the
amount of endogenous GADPH mRNA. A significant increase in the level of RAB28 was observed for all samples under reduced-serum
conditions compared to standard growth conditions (**P = 0.001815 for control; *P = 0.007181 for IV-1; **P = 0.003329 for IV-3). Three
independent experiments were performed with similar results. Statistical analysis was performed using t-tests. (B) Ciliary localization of
RAB28 is significantly reduced in patient cell lines. IFM analysis of control and patient cells grown under reduced-serum conditions. Cilia
were labeled with anti-acetylated alfa-tubulin (AC-TUB) antibody (red). RAB28 protein (green) can be observed in the cilia in the two control
cells (white arrows), whereas none of the three displayed patient cells (IV-1) shows ciliary localization of RAB28. Nuclei were visualized with
DAPI staining (blue). The ciliary localization of RAB28 was significantly reduced in both patient cell lines compared to control (see Table 2).
Scale bar, 10 μm. (C) siRNA-mediated knock down of RAB28 leads to a reduction of ciliary RAB28. Normalized expression profile of RAB28
mRNA expression in control cells treated with siRNA is compared with RAB28 (siRAB28) and a negative control (siScramble) grown under
serum reduced conditions. Expression profiles of RAB28 were normalized to the amount of endogenous GAPDH mRNA. The expression level
in control cells grown under standard conditions treated with siScramble is set to 1. Treatment with siRab28 decreases RAB28 expression by
75.76 ± 2% under reduced-serum conditions (see Table 2). GADPH, glyceraldehyde 3-phosphate dehydrogenase; AC-TUB, anti-acetylated
alfa-tubulin; IFM, immunofluorescence microscopy.
of ciliated cells. Cilia were identified on 79% (124/156) of
the control cells grown under reduced-serum conditions
(Table 2). Cells from IV-1 had 80% ciliated cells (142/165),
whereas cells from IV-3 had 86% ciliated cells (179/223).
Also, control cells treated with siRNA against RAB28 mRNA
had a percentage of ciliated cells similar to that found for
control cells treated with siScramble: 77% (128/166) versus
69% (104/155) (Table 2). Thus, no significant difference in
ciliogenesis was observed.
Investigation of the expression level of RAB28 mRNA
in siRNA-treated cells confirms the specificity of siRNA
against RAB28. The treatment leads to a significant reduction
(75.76 ± 2%) in RAB28 expression, although it did not
completely ablate it (Fig. 4C).
In conclusion, these data underline the pathogenicity of
the RAB28 variant by showing reduced ciliary localization of
RAB28 protein. In contrast, the RAB28 variant did not affect
ciliogenesis.
DISCUSSION
We have described a family with several clinical features
including CRD, PAP, high myopia, at least two forms of
dyschromatopsia, and prostate cancer. Brothers IV-1 and IV-
3 had all of the above-mentioned clinical features, and the
third brother (IV-2) had myopia, deuteranomaly (green), and
prostate cancer. Because the father (III-2) also suffered from
prostate cancer and myopia, we consider these symptoms
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to be inherited independent of the CRD. Apart from IV-2, a
maternal uncle also had deuteranomaly (green), suggesting
the presence of an X-linked form of deuteranomaly in these
two individuals. The finding of a homozygous missense vari-
ant in RAB28 affecting one of the invariable amino acids in
the G motif makes this a plausible explanation for the CRD.
PAP has not previously been reported as a clinical symp-
tom in individuals with RAB28 variants. We speculate that
the RAB28 variant is the cause of PAP in the brothers
presented here because RAB28 locates to the cilia like many
products of genes associated with PAP, another small GTPase
(Rab34) has been shown to be associated with PAP in
mice,18 and, finally, IFT27 (which belongs to the RAB family
of genes) is associated with BBS presenting with PAP.19 We
cannot, however, rule out that another recessive gene is caus-
ing the PAP, especially as the parents are consanguineous.
Five other disease-causing RAB28 variants have been
reported previously: two missense variants, p.Ser23Phe in
a female of Korean descent20 and p.Cys217Trp in a female
of Spanish descent21; two nonsense variants: p.Glu189* and
p.Arg137* in a German and a Moroccan Jewish family,
respectively6; and, finally, a splice variant c.172+1G>C in
a Spanish family21 (Table 3). Classification according to the
ACMG guidelines9 renders the two missense variants as vari-
ants of unknown significance, and the two nonsense variants
and the splice site variant are classified as likely pathogenic.
The ophthalmological findings are very similar with early
onset of macula dystrophy, dyschromatopsia, progressive
visual loss, (high) myopia, and lack of night blindness in
all affected individuals. Thus, it seems that different types of
RAB28 variants (missense, nonsense, and splice) are a cause
of CRD in different ethnic groups.
As mentioned above, the RAB28 missense variant found
in this study, p.Gly19Arg, reduced the amount of RAB28
localized to the cilium but did not seem to alter ciliogen-
esis in human dermal fibroblasts. The observed increase
in RAB28 mRNA expression in the human fibroblasts after
serum starvation is consistent with localization of RAB28
in the cilium. Our observations are in agreement with the
results from Jensen et al.,3 who showed that rab-28 in C.
elegans is not a core component of the BBSome or the
IFT pathway. Rather, it could be speculated that RAB28
associates with the BBSome and the IFT in order to be
transported into the cilia, where it exerts its function. The
BBSome is a highly conserved protein complex essential for
IFT in both humans and mice.22–24 In mice, RAB28 functions
in the cilia and is required for phagocytosis of the discs in
the outer segments of the photoreceptors.17 The same mech-
anism may be present in humans.
As the variant described in this study does not affect the
ability of a cell to form a cilium, further experiments are
necessary to verify whether the ultrastructure of the cilium
is normal in the patient cell lines.
In conclusion, RAB28 variants are a rare cause of CRD
in various ethnic groups. These variants cause a comparable
ophthalmological phenotype and furthermore could also be
a cause of PAP.
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